MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
8.34
-1.59
-16.01%
After Hours: 9.40 +1.06 +12.71% 19:59 05/08 EDT
OPEN
9.65
PREV CLOSE
9.93
HIGH
9.93
LOW
7.85
VOLUME
3.00M
TURNOVER
--
52 WEEK HIGH
19.15
52 WEEK LOW
3.920
MARKET CAP
70.99M
P/E (TTM)
3.245
1D
5D
1M
3M
1Y
5Y
1D
HubSpot, Atara, Upwork, Fastly, Planet Fitness Trending With Analysts
TipRanks · 1d ago
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 1d ago
Atara Biotherapeutics Raised to Buy From Hold by Canaccord Genuity
Dow Jones · 1d ago
Atara Biotherapeutics Price Target Raised to $13.00/Share From $6.00 by Canaccord Genuity
Dow Jones · 1d ago
Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13
Benzinga · 1d ago
ATARA BIOTHERAPEUTICS INC <ATRA.O>: CANACCORD GENUITY RAISES TO BUY FROM HOLD; RAISES TARGET PRICE TO $13 FROM $6
Reuters · 2d ago
ATRA Crosses Above Average Analyst Target
NASDAQ · 2d ago
Atara Biotherapeutics upgraded to Buy from Hold at Canaccord
TipRanks · 2d ago
More
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.